Sirolimus clinical trials: what human data actually shows

Last updated 2026-07-27

Is there a human clinical trial proving rapamycin extends lifespan?

No. As of 2025, there is no completed randomized controlled trial in humans showing sirolimus (rapamycin) extends lifespan or healthspan. This is the single most important fact in the entire rapamycin longevity conversation, and it's worth stating plainly before anything else. What exists instead is a chain of inference: strong, repeated lifespan extension in mice, a plausible mechanism (mTOR inhibition), decades of human safety data from transplant medicine at much higher continuous doses, and a handful of small, short human trials looking at biomarkers, not lifespan. Nobody has run, or completed, a trial that dosed healthy humans with low-dose intermittent rapamycin for years and measured mortality or age-related disease incidence against placebo. That trial would take a long time and a lot of money, and funding a healthy-aging endpoint study is notoriously hard because regulators don't recognize 'aging' as an indication ^[1]. The FDA has approved sirolimus (brand name Rapamune) since 1999 for kidney transplant rejection prophylaxis, and related formulations (Fyarro, Hyftor) for specific tumor and skin conditions ^[2]. None of those approvals cover longevity or anti-aging use. Every low-dose, intermittent-dosing protocol discussed in the longevity space is off-label.

What does the mouse data actually show, and how strong is it?

The mouse data is genuinely strong, and it's the real anchor for the whole rapamycin longevity hypothesis. The National Institute on Aging's Interventions Testing Program (ITP), a multi-site, replicated study design across three labs (Jackson Laboratory, University of Michigan, University of Texas Health Science Center), tested rapamycin starting at different ages in genetically heterogeneous mice. The ITP's 2009 paper reported that rapamycin, fed beginning at 600 days of age (roughly equivalent to a 60-year-old human), extended median lifespan by 9% in females and 13% in males, even though treatment started late in life ^[3]. Later ITP cohorts starting rapamycin earlier and at higher doses showed larger effects, up to around 23% median lifespan extension in some cohorts ^[4]. This is unusually strong reproducibility for a lifespan intervention. Very few compounds tested by the ITP show consistent effects across all three sites and both sexes. That's the real reason rapamycin gets taken seriously in longevity science, not marketing. But mice are not humans. Mice live two to three years; the ITP can get a full lifespan readout in a few years. A comparable human trial would need decades or surrogate endpoints, which is exactly why nobody has done it.

What is the PEARL trial and what did it actually find?

PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is the most-cited human rapamycin trial in the longevity community, and it's worth being precise about its scope. It was a community-funded, randomized, double-blind, placebo-controlled trial run by Dr. Alan Green's team and colleagues, in adults aged 50 to 85, testing low-dose intermittent rapamycin (5mg or 10mg weekly) against placebo over roughly 48 weeks ^[5]. PEARL did not measure lifespan or mortality. It measured biomarkers: lean body mass, bone mineral density by DEXA scan, blood pressure, facial skin appearance, and other functional and metabolic measures. Results, released around 2024, reported some improvements in lean tissue mass and self-reported measures, alongside no serious adverse events attributable to treatment at these doses, but the trial was small (in the range of 100-115 participants) and short relative to human lifespan, and results have had limited peer-reviewed publication depth compared to what a mortality trial would require ^[5]. PEARL is useful as an early safety and biomarker signal in a longevity-motivated population. It is not evidence that rapamycin extends human lifespan or prevents age-related disease. Treat it as hypothesis-generating, not confirmatory.

What do we know about rapamycin safety from decades of transplant use?

This is actually the deepest well of human data on sirolimus, and it matters a lot for safety reasoning even though transplant dosing is very different from longevity dosing. Sirolimus has been used continuously, at doses producing blood trough levels far higher than typical off-label longevity protocols, in transplant patients since FDA approval in 1999 ^[2]. The FDA label for Rapamune documents the core risks at transplant doses: increased susceptibility to infection, delayed wound healing, elevated lipids, mouth ulcers (stomatitis), interstitial lung disease, and increased risk of certain cancers with long-term immunosuppression. These are real, dose-dependent, well-documented risks, not theoretical ones. The longevity community's argument is that intermittent, low, weekly dosing (as opposed to continuous daily transplant dosing) preferentially inhibits mTORC1 while sparing mTORC2, reducing metabolic and immune side effects while retaining benefit. This is a plausible pharmacological hypothesis based on preclinical work, but it has not been validated by a large human outcomes trial. The transplant literature tells you what continuous high-dose sirolimus does over years. It does not directly tell you what 5-6mg once a week does over decades, because that protocol has not been tracked at scale.

What are the real risks of off-label intermittent rapamycin dosing?

Three risk categories come up consistently in both the transplant literature and early longevity-use reports: immune suppression, mouth ulcers, and metabolic shifts. Immune suppression is the mechanistic core of the drug. mTOR inhibition dampens T-cell proliferation, which is exactly why sirolimus prevents transplant rejection. At low intermittent doses, the immune effect is presumed to be much smaller, but there is no large human safety trial confirming what infection risk looks like over years of weekly dosing in otherwise healthy people. Caution around vaccine timing and active infections is standard practical guidance among prescribing physicians, even at low doses. Stomatitis (mouth ulcers) is one of the most commonly reported side effects at any sirolimus dose, including intermittent longevity protocols. It's listed explicitly in the FDA label for Rapamune as a common adverse reaction, and it shows up anecdotally and in PEARL-adjacent reporting as the most frequent complaint even at low weekly doses. Metabolic effects include increased LDL cholesterol and triglycerides and, less predictably, effects on glucose tolerance and insulin sensitivity; some studies show impaired glucose tolerance with rapamycin, which is a genuine point of tension with the longevity hypothesis, since metabolic dysfunction is itself an aging risk factor. This is why anyone using it off-label should be tracking a lipid panel and fasting glucose, more than taking it and hoping. Anyone considering this needs a real conversation with a prescriber about baseline labs and monitoring cadence, not a forum thread. If you're weighing a specific protocol, our Sirolimus Rx dosage guide and Sirolimus Rx cycle length piece cover how intermittent schedules are typically structured, but structuring a dose is not the same as having outcome data on it.

Are there any ongoing human rapamycin trials for aging or longevity?

Yes, several are registered or underway, though none report mortality as a near-term endpoint, because that's not realistic on current timelines. Trials registered on ClinicalTrials.gov have investigated rapamycin's effects on skin aging, periodontal disease, muscle and physical function in older adults, and immune response to vaccination in the elderly ^[6]. One notable line of work is from the University of Washington's Dog Aging Project and earlier UW-led work on rapamycin, which found improved cardiac function markers in middle-aged to older healthy pet dogs given short-term low-dose rapamycin, published in GeroScience in 2017 ^[7]. Dogs share our households and environments in a way mice don't, which makes this data point interesting, but it's still not human data, and it was a small, short trial (10 weeks of dosing). In humans, a trial from Novartis and collaborators (using an mTOR inhibitor, RAD001/everolimus, a close chemical relative of rapamycin) found that low-dose mTOR inhibition improved influenza vaccine response in elderly subjects, published in Science Translational Medicine in 2014. This is often cited as indirect human evidence that mTOR inhibition can improve, more than suppress, certain immune functions in older adults. It's a real and interesting finding, but it's about vaccine response, not lifespan.

Why hasn't anyone run a full human lifespan trial for rapamycin?

Money, time, and regulatory structure, in that order. A trial designed to detect a mortality or major-disease-incidence difference in humans would need thousands of participants followed for many years, likely a decade or more, at a cost plausibly running into hundreds of millions of dollars given typical late-phase trial economics. The FDA does not currently recognize 'aging' itself as an indication a drug can be approved to treat, which removes the normal commercial incentive (patent-protected, FDA-approved indication) that funds phase 3 trials. This regulatory gap is widely discussed in the geroscience field; the TAME trial (Targeting Aging with Metformin), which aimed to get FDA to accept aging-related outcomes as a trial endpoint using a different drug, has been proposed partly to solve this exact problem for the field broadly . Sirolimus is also off-patent (generic since the mid-2000s), which removes the profit incentive a pharmaceutical company would otherwise have to fund an expensive trial. Nobody stands to make patent-protected billions from proving generic rapamycin extends life, so the trial funding has to come from philanthropy, crowdfunding (as with PEARL), or public science budgets, all of which are much smaller pools of money than a for-profit drug development budget.

How does the human evidence compare to the mouse evidence?

What would it take for rapamycin to get an aging indication or a definitive human trial?

Realistically, it would take either a large philanthropic or government-funded trial explicitly designed around an aging-related composite endpoint (frailty, multimorbidity onset, or similar), or a regulatory shift like the one the TAME trial has pushed for, where FDA accepts a delay in onset of a defined set of age-related diseases as an approvable endpoint . Until something like that happens, expect the evidence base to keep growing in the same shape it has for the last decade: more mouse and companion-animal data, more small human biomarker trials, and continued extrapolation from transplant safety data. That's not a criticism of the researchers involved; it's a structural funding and regulatory problem, not a science problem.

What should someone using rapamycin off-label for longevity actually know before starting?

Know exactly what you have and don't have. You have strong mouse data, plausible mechanism, and decades of transplant-dose human safety data. You do not have a completed human trial linking any specific off-label dose or schedule to a lifespan or healthspan benefit. That means the responsible way to use it, if you choose to, is under a prescriber's supervision, with baseline and periodic labs (lipids, glucose, complete blood count, kidney function), attention to infection symptoms and dental health given the mouth ulcer risk, and clear expectations that you're participating in an off-label experiment informed by good preclinical data, not following a proven human protocol. Sirolimus Rx works with prescribers to provide medical oversight for exactly this kind of off-label use, matching patients to a provider-reviewed dosing approach and fulfilling through a licensed pharmacy partner rather than offering it as a self-directed purchase. If you're at the point of deciding on a specific dose, our Sirolimus Rx dosage calculator and guidance on Sirolimus Rx injection sites and how to reconstitute Sirolimus Rx cover the practical side, but none of that substitutes for a prescriber reviewing your labs and history first.

Is sirolimus the same thing as rapamycin?

Yes. Sirolimus is the generic drug name; rapamycin is the original name given to the compound when it was discovered in a soil sample from Easter Island (Rapa Nui) in the 1970s, isolated from the bacterium Streptomyces hygroscopicus. They are the same molecule. 'Rapamycin' tends to be used in scientific and longevity contexts, 'sirolimus' is the pharmaceutical and prescribing name used on FDA labeling and in clinical settings ^[2]. You'll see both terms throughout the literature interchangeably, and that's not an error, it's just naming history.

Frequently asked questions

Has rapamycin been proven to extend human lifespan in a clinical trial?

No. No completed human trial has measured lifespan or mortality outcomes for rapamycin. The strongest lifespan data comes from mouse studies run by the NIA Interventions Testing Program, which showed 9-23% median lifespan extension depending on cohort and start age. Human trials so far measure biomarkers like bone density and lean mass, not survival.

What is the PEARL trial and is it proof rapamycin works in humans?

PEARL is a small, crowdfunded, placebo-controlled human trial (roughly 100-115 adults aged 50-85) testing low-dose weekly rapamycin over about 48 weeks. It measured biomarkers like lean mass and bone density, not lifespan, and reported no serious treatment-related adverse events. It's a useful early signal, not proof of a longevity benefit.

What did the NIA Interventions Testing Program find about rapamycin and mice?

The NIA's Interventions Testing Program, run across three independent labs, found rapamycin extended median mouse lifespan by roughly 9-13% when started at 600 days of age, with later cohorts starting earlier or using higher doses showing up to about 23% extension. It's one of the most reproducible lifespan-extension results the ITP has ever recorded.

Is rapamycin FDA-approved for anti-aging use?

No. Sirolimus is FDA-approved as Rapamune for kidney transplant rejection prophylaxis (since 1999), and related mTOR inhibitor formulations are approved for specific tumors and skin conditions (Fyarro, Hyftor). No formulation is approved for aging, longevity, or anti-aging use; all such use is off-label.

What are the main side effects of low-dose intermittent rapamycin?

Mouth ulcers (stomatitis) are the most commonly reported side effect even at low intermittent doses. Other documented risks, mostly from higher continuous transplant dosing, include increased infection susceptibility, elevated cholesterol and triglycerides, delayed wound healing, and impaired glucose tolerance in some studies.

Does rapamycin suppress the immune system at longevity doses?

Immune suppression is rapamycin's core mechanism at transplant doses, and it's the reason it prevents organ rejection. At low, intermittent, longevity-style dosing the effect is presumed much smaller, but there's no large human trial confirming actual infection rates at these doses over years, so caution around active infections and vaccine timing is standard practice.

Are sirolimus and rapamycin the same drug?

Yes. Rapamycin is the compound's original name, discovered in a Streptomyces hygroscopicus bacterium from Easter Island soil in the 1970s. Sirolimus is its generic pharmaceutical name used on FDA labeling. They are chemically identical; the terms are used interchangeably in research and longevity discussions.

Why hasn't a full human lifespan trial for rapamycin been done yet?

Cost and regulatory structure. A mortality-endpoint trial would need thousands of participants over a decade or more, likely costing hundreds of millions of dollars, and the FDA doesn't currently recognize aging itself as an approvable indication. Since sirolimus is generic and off-patent, there's no company with a profit incentive to fund that trial.

What does transplant medicine tell us about long-term rapamycin safety?

Sirolimus has been used continuously in transplant patients since 1999 at doses much higher than longevity protocols. That experience documents real risks: infection susceptibility, delayed wound healing, elevated lipids, mouth ulcers, and certain cancer risks with long-term immunosuppression. It doesn't directly predict outcomes at low, weekly, longevity-style dosing.

Is there animal data on rapamycin besides mice?

Yes. A University of Washington-led study published in GeroScience in 2017 found short-term, low-dose rapamycin improved cardiac function markers in healthy middle-aged to older pet dogs over 10 weeks. It's a small, short study, but notable because dogs share human-like environments, unlike lab mice.

Can rapamycin improve immune function instead of just suppressing it?

Possibly, in a specific way. A 2014 Science Translational Medicine trial found low-dose treatment with everolimus, a close relative of rapamycin, improved influenza vaccine response in elderly subjects. This suggests mTOR inhibition may selectively dampen some immune pathways while improving others, but it's one trial on vaccine response, not a general immune-boosting claim.

What labs should someone monitor while using rapamycin off-label?

Prescribers typically track a lipid panel (cholesterol, triglycerides), fasting glucose, complete blood count, and kidney function, given rapamycin's documented effects on metabolism and immune cells at higher doses. There's no standardized monitoring protocol validated specifically for low-dose longevity use, so this follows best clinical judgment extrapolated from transplant dosing guidance.

Sources

1. National Institute on Aging, Interventions Testing Program overview: Aging is not currently an FDA-recognized drug indication, complicating longevity trial funding
2. FDA, Rapamune (sirolimus) approval history: Sirolimus was FDA-approved as Rapamune for kidney transplant rejection prophylaxis in 1999
3. Harrison et al., Nature, 2009: Rapamycin fed starting at 600 days of age extended median lifespan 9% in females and 13% in males in ITP mice
4. NIA Interventions Testing Program results summary: Later ITP rapamycin cohorts with earlier start ages or higher doses showed up to roughly 23% median lifespan extension
5. PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity): PEARL is a randomized, placebo-controlled trial of low-dose intermittent rapamycin in adults 50-85 measuring biomarkers, not lifespan
6. Urfer et al., GeroScience, 2017: Short-term low-dose rapamycin improved cardiac function markers in healthy middle-aged to older dogs over 10 weeks
7. Mannick et al., Science Translational Medicine, 2014: Low-dose mTOR inhibition with an everolimus-based regimen improved influenza vaccine response in elderly subjects